- Home
- EDN vs KALV Comparison
EDN vs KALV Comparison
Compare EDN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- KALV
- Stock Information
- Founded
- EDN 1992
- KALV N/A
- Country
- EDN Argentina
- KALV United States
- Employees
- EDN N/A
- KALV N/A
- Industry
- EDN Electric Utilities: Central
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- KALV Health Care
- Exchange
- EDN Nasdaq
- KALV Nasdaq
- Market Cap
- EDN 675.2M
- KALV 796.4M
- IPO Year
- EDN 2007
- KALV N/A
- Fundamental
- Price
- EDN $15.38
- KALV $11.85
- Analyst Decision
- EDN
- KALV Strong Buy
- Analyst Count
- EDN 0
- KALV 8
- Target Price
- EDN N/A
- KALV $26.43
- AVG Volume (30 Days)
- EDN 202.3K
- KALV 1.5M
- Earning Date
- EDN 08-11-2025
- KALV 09-11-2025
- Dividend Yield
- EDN N/A
- KALV N/A
- EPS Growth
- EDN N/A
- KALV N/A
- EPS
- EDN 0.21
- KALV N/A
- Revenue
- EDN $1,911,272,136.00
- KALV $1,426,000.00
- Revenue This Year
- EDN $37.74
- KALV N/A
- Revenue Next Year
- EDN $27.07
- KALV $213.43
- P/E Ratio
- EDN $4.06
- KALV N/A
- Revenue Growth
- EDN 23.18
- KALV N/A
- 52 Week Low
- EDN $14.38
- KALV $7.30
- 52 Week High
- EDN $51.69
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- EDN 36.20
- KALV 34.25
- Support Level
- EDN $14.38
- KALV $11.93
- Resistance Level
- EDN $20.70
- KALV $12.43
- Average True Range (ATR)
- EDN 1.33
- KALV 0.56
- MACD
- EDN 0.10
- KALV -0.19
- Stochastic Oscillator
- EDN 15.87
- KALV 11.44
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.